Effects of Interleukin-2 and Interferon Alfa-2a in Cancer Patients
Author Information
Author(s): G. Pichert, L.M. Jost, W. Fierz, R.A. Stahel
Primary Institution: University Hospital, Zurich, Switzerland
Hypothesis
Does alternative weekly treatment with interleukin-2 and interferon alfa-2a improve outcomes in patients with advanced renal cell carcinoma and melanoma?
Conclusion
The study found that the treatment resulted in moderate toxicity but limited tumor responses, particularly in melanoma patients.
Supporting Evidence
- Two patients with melanoma had a partial response lasting 1-7 months.
- 36% of patients developed autoimmune thyroiditis.
- Treatment resulted in an average weight loss of 5%.
Takeaway
Doctors tested a new treatment for cancer using two medicines, but it didn't work very well for most patients.
Methodology
Patients received interleukin-2 and interferon alfa-2a in a phase II study, with treatment cycles assessed for tumor response and immune effects.
Potential Biases
Potential bias due to the small number of patients and lack of a control group.
Limitations
The study had a small sample size and limited responses in renal cell carcinoma.
Participant Demographics
14 patients, 6 with renal cell carcinoma and 8 with melanoma, mean age 47 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website